Clinically relevant genetic variations in drug metabolizing enzymes.
暂无分享,去创建一个
[1] F Demard,et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[3] M. Kato,et al. Intestinal first-pass metabolism of CYP3A4 substrates. , 2008, Drug metabolism and pharmacokinetics.
[4] W. Weber,et al. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Lafitte,et al. Evidence for CYP2D6 expression in human lung. , 1997, Biochemical and biophysical research communications.
[6] E. Schuetz,et al. Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.
[7] U. Klotz,et al. Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.
[8] J. O’Connell,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.
[9] J. Schenkman,et al. Dissection of cytochrome P-450 isozymes (RLM) from fractions of untreated rat liver microsomal proteins. , 1982, Biochemical and biophysical research communications.
[10] N. Sládek,et al. Induction of drug metabolism. I. Differences in the mechanisms by which polycyclic hydrocarbons and phenobarbital produce their inductive effects on microsomal N-demethylating systems. , 1969, Molecular pharmacology.
[11] J. S. Miles,et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.
[12] R. Kim,et al. CYP2C9 allelic variants: ethnic distribution and functional significance. , 2002, Advanced drug delivery reviews.
[13] C. Clayman,et al. 4. TOXICITY OF PRIMAQUINE IN NEGROES , 1952 .
[14] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[15] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[16] B. Lacarelle,et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity , 2010, Cancer Chemotherapy and Pharmacology.
[17] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[18] S. Hunt,et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.
[19] N. Sládek,et al. Induction of Drug Metabolism: II. Qualitative Differences in the Microsomal N-Demethylating Systems Stimulated by Polycyclic Hydrocarbons and by Phenobarbital , 1969 .
[20] J. Dungan,et al. Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen , 2010 .
[21] C. Guillemette,et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.
[22] V. McKusick,et al. Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.
[23] Shufeng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.
[24] R. Weinshilboum,et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.
[25] R. Preisig,et al. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man , 2004, European Journal of Clinical Pharmacology.
[26] C. Clayman,et al. Toxicity of primaquine in Caucasians. , 1952, Journal of the American Medical Association.
[27] C. Gieger,et al. Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.
[28] M. Farmen,et al. Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans , 2010, Journal of clinical pharmacology.
[29] N. Benowitz,et al. Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African‐American Light Smokers , 2009, Clinical pharmacology and therapeutics.
[30] J. Boullata,et al. Handbook of drug-nutrient interactions. , 2004 .
[31] M Schwab,et al. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.
[32] T. Jiang,et al. Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders , 2010, Psychiatric Genetics.
[33] D. Flockhart,et al. Drug Interactions and the Cytochrome P450 System , 1995, Clinical pharmacokinetics.
[34] C. Clayman,et al. 3. TOXICITY OF PRIMAQUINE IN CAUCASIANS , 1952 .
[35] J. Menke. Drug interactions and the cytochrome P-450 system. , 2000, South Dakota journal of medicine.
[36] G. Hitchings,et al. STUDIES ON ANALOGS OF PURINES AND PYRIMIDINES , 1950, Annals of the New York Academy of Sciences.
[37] C. Day,et al. Genetic association studies in drug-induced liver injury. , 2009, Seminars in liver disease.
[38] E. Beutler,et al. Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A. , 1990, American journal of human genetics.
[39] M. Eichelbaum,et al. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.
[40] L. H. Schmidt,et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. , 1954, American review of tuberculosis.
[41] U. Meyer,et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. , 1990, American journal of human genetics.
[42] A. V. van Kuilenburg. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. , 2004, European journal of cancer.
[43] R. Knight,et al. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. , 1958, American review of tuberculosis.
[44] Hein Putter,et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] U. Meyer,et al. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.
[46] B. Goh,et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients , 2007, Cancer science.
[47] B. Giusti,et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis , 2011, The Pharmacogenomics Journal.
[48] H. Jörnvall,et al. Recommended nomenclature for the vertebrate alcohol dehydrogenase gene family. , 1999, Biochemical pharmacology.
[49] A. Motulsky. Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.
[50] N. Geller,et al. Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial , 2010, Clinical trials.
[51] R. Diasio,et al. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] M. Rawlins,et al. Gilbert’s Syndrome and Drug Metabolism , 1979, Clinical pharmacokinetics.
[53] J. Idle,et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.
[54] 西尾 由貴子. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome , 2011 .
[55] M. Gawaz,et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. , 2008, Pharmacogenomics.
[56] M. Eichelbaum,et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.
[57] M. Boyd,et al. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. , 2002, Brain research. Molecular brain research.
[58] C. Clayman,et al. Toxicity of primaquine in Negroes. , 1952, Journal of the American Medical Association.
[59] Y. Hasegawa,et al. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. , 2007, Current opinion in molecular therapeutics.
[60] Fergus J Couch,et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] D. Grant,et al. Changes in consensus arylamine N-acetyltransferase gene nomenclature. , 2008, Pharmacogenetics and genomics.
[62] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[63] A. Kastrati,et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.
[64] J. W. Findlay,et al. Analgesie drugs in breast milk and plasma * , 1981, Clinical pharmacology and therapeutics.
[65] R. Neubig,et al. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature , 2009, Pharmacological Reviews.
[66] H. Edenberg. The Genetics of Alcohol Metabolism: Role of Alcohol Dehydrogenase and Aldehyde Dehydrogenase Variants , 2007, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.
[67] R. Weinshilboum,et al. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.
[68] I. Mlinarič-Raščan,et al. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. , 2009, Pharmacogenomics.
[69] L. Wienkers,et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[70] K. Brøsen. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. , 1995, Clinical Pharmacokinetics.
[71] M. J. Coon,et al. Position-specific oxygenation of benzo(a)pyrene by different forms of purified cytochrome P-450 from rabbit liver. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[72] B. Brodie,et al. Enzymatic metabolism of drugs and other foreign compounds. , 1958, Annual review of biochemistry.
[73] P. Gangadharam,et al. Peripheral neuritis due to isoniazid. , 1960, Bulletin of the World Health Organization.
[74] M. Pirmohamed,et al. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. , 2010, Pharmacogenomics.
[75] B. Carleton,et al. Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study , 2009, Clinical pharmacology and therapeutics.
[76] L. Bertilsson,et al. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine , 1980, European Journal of Clinical Pharmacology.
[77] P. Fasching,et al. CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification , 2010, Clinical Cancer Research.
[78] H. McLeod,et al. Should DPD analysis be required prior to prescribing fluoropyrimidines? , 2007, European journal of cancer.
[79] M. Goetz,et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. , 2009, Cancer research.
[80] E. Sim,et al. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. , 1991, Biochemical pharmacology.
[81] D. Flockhart,et al. The Star‐Allele Nomenclature: Retooling for Translational Genomics , 2007, Clinical pharmacology and therapeutics.
[82] L. Bertilsson,et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.
[83] Shiew-Mei Huang,et al. A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity , 2009, Journal of clinical pharmacology.
[84] N. Sapeika,et al. The Excretion of Drugs in Human Milk—A Review , 1947, The Journal of obstetrics and gynaecology of the British Empire.
[85] Martin R. Johnson,et al. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[86] H. McLeod,et al. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. , 2009, Pharmacogenomics.
[87] D. Waxman,et al. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[88] M. Tomšič,et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients , 2008, European Journal of Clinical Pharmacology.
[89] J. Horowitz,et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial data , 2010, Journal of thrombosis and haemostasis : JTH.
[90] R. Estabrook,et al. Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems , 1965, Science.
[91] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[92] J. Halperin,et al. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.
[93] Tyson A. Clark,et al. Genetic architecture of transcript-level variation in humans. , 2008, American journal of human genetics.
[94] B. Alexanderson,et al. Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.
[95] M. Zhan,et al. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. , 2007, Cancer detection and prevention.
[96] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[97] T. Langaee,et al. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.
[98] Noam Shomron,et al. MicroRNAs and pharmacogenomics. , 2010, Pharmacogenomics.
[99] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.
[100] T. Nishiyama,et al. Dihydropyrimidine Dehydrogenase Activity in 150 Healthy Japanese Volunteers and Identification of Novel Mutations , 2005, Clinical Cancer Research.
[101] Christina N. Lessov-Schlaggar,et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine , 2006, Clinical pharmacology and therapeutics.
[102] S. B. Koukouritaki,et al. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. , 2005, Pharmacogenomics.
[103] R. Weinshilboum,et al. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.
[104] J. Sheller,et al. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. , 1999, The Journal of pharmacology and experimental therapeutics.
[105] D W Nebert,et al. The P450 gene superfamily: recommended nomenclature. , 1987, DNA.
[106] Magnus Ingelman-Sundberg,et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.
[107] A. Daly. Significance of the Minor Cytochrome P450 3A Isoforms , 2006, Clinical pharmacokinetics.
[108] R. Levy. Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.
[109] E. Beutler,et al. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[110] Guoying Tai,et al. The pharmocogenomics of warfarin: closing in on personalized medicine. , 2006, Molecular interventions.
[111] Martin R. Johnson,et al. Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test , 2004, Clinical Cancer Research.
[112] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[113] T. Prueksaritanont,et al. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver. , 1995, Biochemical pharmacology.
[114] D W Nebert,et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. , 1991, DNA and cell biology.
[115] J. Cashman,et al. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. , 1994, Archives of biochemistry and biophysics.
[116] R. Diasio,et al. Dihydropyrimidine dehydrogenase deficiency in an Indian population , 2006, Cancer Chemotherapy and Pharmacology.
[117] J. Miller,et al. Substrate-induced synthesis and other properties of benzpyrene hydroxylase in rat liver. , 1957, The Journal of biological chemistry.
[118] B. Burchell,et al. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.
[119] Interethnic dissociation between debrisoquine and desipramine hydroxylation. , 1985, Journal of clinical psychopharmacology.
[120] K. Brøsen,et al. Drug Interactions and the Cytochrome P450 System , 1995 .
[121] Knight Ra,et al. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. , 1958 .
[122] D. Grant,et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[123] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[124] R. Tyndale,et al. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. , 2007, Pharmacogenomics.
[125] Lang Li,et al. CYP2D6 genotype and tamoxifen response , 2005, Breast Cancer Research.
[126] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[127] F. Sjöqvist,et al. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.
[128] M. Leider. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .
[129] Nicole Soranzo,et al. A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.
[130] Elizabeth Pennisi,et al. Genomics. 1000 Genomes Project gives new map of genetic diversity. , 2010, Science.
[131] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[132] U. Klotz,et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. , 2007, Clinical pharmacokinetics.
[133] J. Sludden,et al. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. , 2000, British journal of clinical pharmacology.
[134] P. Carson,et al. Enzymatic deficiency in primaquine-sensitive erythrocytes. , 1956, Science.
[135] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[136] C. Gieger,et al. Sequence variants at CHRNB 3 – CHRNA 6 and CYP 2 A 6 affect smoking behavior , 2010 .
[137] R. Estabrook,et al. The stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. , 1963, The Journal of biological chemistry.
[138] C. Hirschhäuser,et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.
[139] Magnus Ingelman-Sundberg,et al. The human genome project and novel aspects of cytochrome P450 research. , 2005, Toxicology and applied pharmacology.
[140] W. Evans,et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.
[141] L. Alger,et al. Codeine and the Breastfed Neonate , 1993, Journal of human lactation : official journal of International Lactation Consultant Association.
[142] L. Luzzatto,et al. Both mutations in G6PD A- are necessary to produce the G6PD deficient phenotype. , 1992, Human molecular genetics.
[143] S. Yin,et al. Effect of the allelic variants of aldehyde dehydrogenase ALDH2*2 and alcohol dehydrogenase ADH1B*2 on blood acetaldehyde concentrations , 2009, Human Genomics.
[144] T. Omura,et al. A new cytochrome in liver microsomes. , 1962, The Journal of biological chemistry.
[145] A. Bairoch,et al. Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature , 2009, Pharmacogenetics and genomics.
[146] A. V. van Kuilenburg,et al. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. , 2003, Annals of clinical biochemistry.
[147] Gideon Koren,et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. , 2007, Canadian family physician Medecin de famille canadien.
[148] F. Mach,et al. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. , 2008, Thrombosis research.
[149] P. Vreken,et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency , 1999, Human Genetics.
[150] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[151] R. Weinshilboum,et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.
[152] G. Milano,et al. A Rapid and Inexpensive Method for Anticipating Severe Toxicity to Fluorouracil and Fluorouracil-based Chemotherapy , 2006, Therapeutic drug monitoring.
[153] F. Vogel. Moderne Probleme der Humangenetik , 1959 .